Biotechnology

Samsung Biologics Shares 'Vision' for Next Decade at the 39th Annual JP Morgan Healthcare Conference

INCHEON, South Korea, Jan. 13, 2021 /PRNewswire/ -- Samsung Biologics (207940.KS) set forth its dynamic growth plan for the next decade at the 2021 Annual JP Morgan Healthcare Conference.John Rim, newly appointed President and CEO, unveiled a multidimensional business plan for the company to furt...

2021-01-13 23:17 7537

GenScript Submits Application with FDA for Use of cPass™ SARS-CoV-2 Neutralization Antibody Test in Convalescent Plasma Screening

PISCATAWAY, N.J., Jan. 13, 2021 /PRNewswire/ -- GenScript USA Inc., the world's leading research reagent provider, announced today that it has submitted an application to the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) for use of the cPass™ SARS-CoV-2 N...

2021-01-13 20:30 5427

VesCir poised to revolutionize skincare industry at CES 2021 with AI-driven 'iCi' skincare system

TAIPEI, Jan. 12, 2021 /PRNewswire/ -- Taiwanese biotech startup, VesCir, inspired by Nasa's Skin.B project, will have a launch of its ownthis year at CES 2021, where it will showcase its medical grade portable dynamic skincare system; a first on the market. The future of skincare now; "Dynamic...

2021-01-13 09:33 1781

CES 2021 Taiwanese biotech startup mProbe CADx develops AI health analysis platform

TAIPEI, Jan. 12, 2021 /PRNewswire/ -- mProbe Taiwan is a subsidiary biotechnology company of mProbe Inc, committed to promoting human health and wellness by transforming the field of precision health and precision medicine. With multi-omics as the critical evidence, mProbe has endeavored to inter...

2021-01-13 02:49 1635

Happiness Biotech's E-Commerce Business - Happy Buy, Achieved Over 70% Growth in December

NANPING, China, Jan. 11, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that Happy Buy, the Company's wholly-owned subsidiary focusing on e-commerce business, has achiev...

2021-01-11 21:00 6933

PharmAbcine announces a research collaboration with LegoChem Biosciences

DAEJEON, South Korea, Jan. 11, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company has entered into a research collaboration agreement with LegoChem Bioscience...

2021-01-11 21:00 1218

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China

SHANGHAI, Jan. 9, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients inGreater China, announced today the closing of a$150 million Series B financing. The round...

2021-01-09 11:06 5644

Gracell Biotechnologies Announces Pricing of Initial Public Offering

SUZHOU and SHANGHAI, China, Jan. 8, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical ne...

2021-01-08 14:55 9530

Dr David Stamler Appointed CEO

MELBOURNE, Australia, Jan. 7, 2021 /PRNewswire/ -- The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointment of DrDavid Stamler to the role of Chief Executive Office effective immediately. Dr Stamler joined the Company in J...

2021-01-07 21:00 11862

VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China

SHANGHAI, Jan. 7, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, introducing the world's leading treatment methods and drugs into theChina market and hoping to provide more Chinese patients quick access to the world's most a...

2021-01-07 18:45 1482

VolitionRx Limited Awarded an Additional $4 Million in Non-Dilutive Funding

AUSTIN, Texas, Jan. 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it has been awarded additional non-dilutive funding totaling approximately$4 million from the Walloon Region and Namur Invest,Belgium. To date, Agencies from the Walloon Region have a...

2021-01-06 21:25 9567

TurtleTree Labs, the global leader in cell based milk, launches TurtleTree Scientific

SAN FRANCISCO, Jan. 5, 2021 /PRNewswire/ -- TurtleTree Labs, the global leader in cell-based milk, today announced the launch of TurtleTree Scientific, dedicated to the growth of food grade growth factors. Despite the costs of producing cell-based meat declining over the years, the cell culture m...

2021-01-06 06:00 2004

PharmAbcine to participate in BIO @ JPM and Biotech Showcase Digital during "J.P. Morgan Week 2021"

DAEJEON, South Korea, Jan. 4, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in BIO @ JPM and Biotech Showcase during the J.P. Morgan Wee...

2021-01-04 21:00 1708

Happiness Biotech Announces Registered Direct Offering of up to 4.2 Million Ordinary Shares to Strategic Investors

NANPING, China, Jan. 4, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that it has entered into a securities purchase agreement with certain non-U.S. strategic investors...

2021-01-04 21:00 9435

CIMC Enric's Subsidiary Deploys Vaccine Storage Market To Carry out R&D of Cryogenic Liquid Nitrogen Biological Container

SHENZHEN, China, Jan. 4, 2021 /PRNewswire/ -- CIMC Enric Holdings Limited (" CIMC Enric" or "the Company", SEHK stock code: 3899.HK), announced that its subsidiary Zhangjiagang CIMC Sanctum Cryogenic Equipment Co., Ltd ("CIMC Sanctum ") recently started R&D of liquid nitrogen biological containers ...

2021-01-04 16:23 3882

ImmVira Announces Series C Financing with Leading Specialist Investors

SHENZHEN, China, Dec. 31, 2020 /PRNewswire/ -- ImmVira Group Company ("the Company"), a biotechnology platform dedicated to the development of oncolytic virus("OV") and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C fina...

2020-12-31 19:29 3740

Novotech Health Holdings Appoints Zidong Zhang as CFO

SHANGHAI and SYDNEY, Dec. 28, 2020 /PRNewswire/ -- Novotech Health Holdings ("Novotech Holdings"), the largest biotech specialist contract research organization (CRO) inAsia, today announced the appointment of Zidong Zhang as Chief Financial Officer (CFO) effective4 January 2021. Zidong Zhang wil...

2020-12-29 12:00 1796

Arctic Vision obtains the first IND approval for the treatment of UME in China, Suprachoroidal space (SCS) injection potentially brings more benefits to patients

SHANGHAI, Dec. 25, 2020 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company with a leading portfolio of breakthrough technologies, announced on December 24th the clearance of the Investigational New Drug (IND) for Phase III trial of ARVN001 (triamcinolone acetonide s...

2020-12-25 21:00 3383

I-Mab Announces Upcoming Participation at January Conferences

SHANGHAI and GAITHERSBURG, Md., Dec. 23, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in Januar...

2020-12-23 21:00 5796

Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19

SEOUL, South Korea, Dec. 22, 2020 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ symbol: 048410) announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for thepotential treatment of patients with severe ...

2020-12-23 10:09 1714
1 ... 117118119120121122123 ... 133